18F labeling of proteins using sortases
The present invention, in some aspects, provides methods, reagents, compositions, and kits for the radiolabeling of proteins, for example, of proteins useful for positron emission tomography (PET) or single-photon emission computed tomography (SPECT) (e.g., for diagnostic and therapeutic applications), using sortase-mediated transpeptidation reactions. Some aspects of this invention provide methods for the conjugation of an agent, for example, a radioactive agent or molecule to diagnostic or therapeutic peptides or proteins. Compositions comprising sortagged, radiolabeled proteins as well as reagents for generating radiolabeled proteins are also provided. Kits comprising reagents useful for the generation of radiolabeled proteins are provided, as are precursor proteins that comprise a sortase recognition motif.
1. A radioactive protein of Formula (II):
wherein
represents a protein;
L 1 is a peptide linker comprising -LPXTGGGK-, -LPXTGGG-, -NPXTGGGK-, -NPXTGGG-, -LPXTAAA-, -NPXTAAA-, -LPXTGGGGG-, or -LPGAG-, wherein each instance of X is independently any amino acid; and
L 2 is a linker comprising optionally substituted heterocyclylene.
2. A pharmaceutical composition comprising the radioactive protein of claim 1 and a pharmaceutically acceptable carrier.
3. The radioactive protein of claim 1 , wherein is an antibody, a nuclear factor, a neuropeptide, a receptor protein, an enzyme, a structural protein, or a fragment thereof.
4. The radioactive protein of claim 1 , wherein L 1 is -LPXTGGG-.
5. The radioactive protein of claim 1 , wherein L 2 is of Formula (ii):
wherein
R t is hydrogen, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocyclyl;
R s is a bond, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted arylene, optionally substituted heteroarylene, or optionally substituted heterocyclylene;
each instance of R c1 is hydrogen, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocyclyl; or two R c1 are joined to form an optionally substituted carbocyclic or optionally substituted heterocyclic ring;
R c2 is a bond, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted arylene, optionally substituted heteroarylene, or optionally substituted heterocyclylene;
m is 0, 1, 2, 3, 4, 5, 6, 7, or 8, as valency permits;
a is a point of attachment to L 1 ; and
b is a point of attachment to 18 F.
6. The radioactive protein of claim 5 , wherein L 2 is of Formula (ii-a):
wherein n is an integer between 1 and 8, inclusive.
7. The radioactive protein of claim 6 , wherein R t is optionally substituted methyl, optionally substituted pyridine, or optionally substituted phenyl.
8. The radioactive protein of claim 1 , wherein L 2 is of Formula (iii):
wherein
R t is hydrogen, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocyclyl;
R s is a bond, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted arylene, optionally substituted heteroarylene, or optionally substituted heterocyclylene;
each instance of R c1 is hydrogen, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocyclyl;
R c2 is a bond, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted arylene, optionally substituted heteroarylene, or optionally substituted heterocyclylene;
m is 0, 1, 2, 3, 4, 5, 6, 7, or 8, as valency permits;
a is a point of attachment to L 1 ; and
b is a point of attachment to 18 F.
9. The radioactive protein of claim 8 , wherein L 2 is of Formula (iii-a):
10. The radioactive protein of claim 9 , wherein -L 2 - 18 F is of Formula (iii-b):
wherein
each instance of R p is independently hydrogen, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, hydroxyl, or optionally substituted amino; provided at least one RP comprises 18 F; and
p is 1, 2, 3, 4, or 5.
11. The radioactive protein of claim 10 , wherein -L 2 - 18 F is of Formula (iii-b1):
wherein
L 3 is a bond, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted arylene, optionally substituted heteroarylene, or optionally substituted heterocyclylene;
R N1 is independently hydrogen, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted aryl, optionally substituted heteroaryl, or a nitrogen protecting group; and
each of R s1 , R s2 , R s3 , and R s4 is independently hydrogen, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted aryl, optionally substituted heteroaryl, or an oxygen protecting group.
12. The radioactive protein of claim 10 , wherein -L 2 - 18 F is of the formula:
13. The radioactive protein of claim 10 , wherein -L 2 - 18 F is of Formula (iii-b2):
wherein
L 3 is a bond, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted arylene, optionally substituted heteroarylene, or optionally substituted heterocyclylene;
R N1 is independently hydrogen, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, or a nitrogen protecting group;
each instance of R q1 is independently hydrogen, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, hydroxyl, or optionally substituted amino; and
q1 is 0, 1, 2, 3, or 4.
14. The radioactive protein of claim 10 , wherein -L 2 - 18 F is of the formula:
15. The radioactive protein of claim 10 , wherein -L 2 - 18 F is of Formula (iii-b3):
wherein
R N1 is independently hydrogen, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted aryl, optionally substituted heteroaryl, or a nitrogen protecting group; and
each instance of R q2 is independently hydrogen, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, hydroxyl, or optionally substituted amino; and
q2 is 0, 1, 2, 3, or 4.
16. The radioactive protein of claim 15 , wherein -L 2 - 18 F is of the formula:
17. The radioactive protein of claim 1 , wherein -L 2 - 18 F is of Formula (iii-c):
wherein
R t is hydrogen, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocyclyl;
a is a point of attachment to L 1 ;
Y comprises CO, CH 3 CN, CH 3 CH 2 CN, a monosubstituted amine, a disubstituted amine, a trisubstituted amine, pyridine, piperidine, a dialkylcyanamide, triphenylphosphine oxide, THF, DMF, NMF, 1,5-cyclooctadiene, norbornadiene, 1,2-ethylenediamine, tetramethylethylenediamine, 1,2-dimethoxyethane, diglyme, 2,5-dithiahexane, cycloheptatriene, benzene, toluene, xylene, mesitylene, naphthalene, tetraazacyclododecane, diethylenetriamine, trithiocylononane, 1,4,7-triazacyclononane-triacetic acid (NOTA), 1,4,7,10-tetraazacyclododecane-tetraacetic acid (DOTA), or triazacyclononane-phosphinate (TRAP), wherein Y chelates a pharmaceutically acceptable metal complex comprising 18 F; and
L 4 is a bond, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted arylene, optionally substituted heteroarylene, or optionally substituted heterocyclylene.
18. The radioactive protein of claim 17 , wherein -L 2 - 18 F is of Formula (iii-c1):
wherein
M is a pharmaceutically acceptable metal;
each of L a , L b , and L c is independently optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted arylene, optionally substituted heteroarylene, or optionally substituted heterocyclylene; and
--- is a coordination bond or is absent, as valency permits.
19. The radioactive protein of claim 18 , wherein -L 2 - 18 F is of Formula (iii-c2):
20. The radioactive protein of claim 1 , wherein the radioactive protein is one of the following formulae:
wherein M is a pharmaceutically acceptable metal.
21. The radioactive protein of claim 8 , wherein the linker L 2 is of Formula (ii-b):
wherein n is an integer between 1 and 8, inclusive.